BIOMAT Database Logo BIOMAT Database Logo

Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. 1994

W N Dinjens, and M M van der Weiden, and F H Schroeder, and F T Bosman, and J Trapman
Department of Pathology, Erasmus University, Rotterdam, The Netherlands.

We have studied the frequency of mutations in the p53 gene in human prostate cancer. The investigated material consisted of 20 primary-tumor tissue specimens, obtained by transurethral resection and tissue specimens of 15 lymph-node metastases, obtained at total prostatectomy. The applied methods encompassed immunohistochemistry on frozen sections, using the monoclonal antibody PAb 1801, and single-strand conformation polymorphism (SSCP) analysis, after amplification of single exon sequences by PCR, on exons 5 to 8 of the p53 gene. The mutations, leading to aberrantly migrating bands in the PCR-SSCP analysis, were identified by direct sequencing of the PCR product. Immunohistochemical and PCR-SSCP analysis were completely confirmative. In the primary tumors, mutations were found in 10% of the specimens (codons 232 and 273), and in lymph-node metastases in 15% of the specimens (codons 248 and 273). In one case (codon 273), the same mutation was found both in the primary tumor and in the lymph-node metastasis. Our results show that p53 mutations are infrequent in both primary and metastatic prostate tumors. In addition, they indicate that there is no strict correlation between p53 mutation and tumor metastasis.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D003062 Codon A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (CODON, TERMINATOR). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, TRANSFER) complementary to all codons. These codons are referred to as unassigned codons (CODONS, NONSENSE). Codon, Sense,Sense Codon,Codons,Codons, Sense,Sense Codons
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein

Related Publications

W N Dinjens, and M M van der Weiden, and F H Schroeder, and F T Bosman, and J Trapman
Frequency and characterization of p53 mutations in clinically localized prostate cancer.
March 1995, Urology,
W N Dinjens, and M M van der Weiden, and F H Schroeder, and F T Bosman, and J Trapman
Association of p53 mutations with metastatic prostate cancer.
October 1995, Clinical cancer research : an official journal of the American Association for Cancer Research,
W N Dinjens, and M M van der Weiden, and F H Schroeder, and F T Bosman, and J Trapman
p53 mutations in matched primary and metastatic human tumors.
July 1995, Molecular carcinogenesis,
W N Dinjens, and M M van der Weiden, and F H Schroeder, and F T Bosman, and J Trapman
P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
July 1996, British journal of cancer,
W N Dinjens, and M M van der Weiden, and F H Schroeder, and F T Bosman, and J Trapman
High frequency of gene mutations in metastatic prostate cancer.
August 2016, The Lancet. Oncology,
W N Dinjens, and M M van der Weiden, and F H Schroeder, and F T Bosman, and J Trapman
Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors.
December 1998, Cancer,
W N Dinjens, and M M van der Weiden, and F H Schroeder, and F T Bosman, and J Trapman
p53 oncogene mutations in human prostate cancer specimens.
February 1994, The Journal of urology,
W N Dinjens, and M M van der Weiden, and F H Schroeder, and F T Bosman, and J Trapman
Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases.
August 1997, Clinical cancer research : an official journal of the American Association for Cancer Research,
W N Dinjens, and M M van der Weiden, and F H Schroeder, and F T Bosman, and J Trapman
Tumor suppressor gene p53 mutations in human prostate cancer.
July 1995, The Prostate,
W N Dinjens, and M M van der Weiden, and F H Schroeder, and F T Bosman, and J Trapman
p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential.
January 1999, The Journal of urology,
Copied contents to your clipboard!